Alex L. T. Imholz
19 Papers
8 Citations
Alex L. T. Imholz is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
A. van der Voort,Fleur M Louis,Mette S. van Ramshorst,R. Kessels,I.A.M. Mandjes,Inge Kemper,Mariette J. Agterof,Wim A. van der Steeg,Joan B Heijns,Marlies L. van Bekkum,Ester JM Siemerink,Philomeen M Kuijer,A. Scholten,J. Wesseling,Marie-Jeanne T F D Vrancken Peeters,Ritse M. Mann,G. Sonke,E. van Leeuwen-Stok,L. van Leeuwen,H. de Graaf,Johanna M. G. H. van Riel,D. Houtsma,Suzan Vrijaldenhoven,A.W.G. van der Velden,A.L. Peerdeman,R.J. van den Brink - Schimmel,Jan C. Drooger,Alex L. T. Imholz,M W Dercksen,Jamal Oulad Hadj,S.D. Bakker,A. J. van der Wouw,E. Kerver,G. Bouma,C. van Schaik,M. de Boer,Caroline M.P.W. Mandigers,R. Koornstra,A. Smals,R. C. Rietbroek,A. van der Padt - Pruijsten,M.O. den Boer,H. Bos,P. P. Schiphorst,Birgit E.P.J. Vriens,Q.C. van Rossum,J. Tol,D. Hoogwerf - Kluft,C.M.F. Kruijtzer - Schimmel,HM Oosterkamp,I.O. Baas,A.H.P. Dietvorst,M. Davidis - van Schoonhoven,M.A. van Dijk +53 more
TL;DR: A third of patients with stage II-III hormone receptor-negative and HER2-positive breast cancer had a complete pathological response after only three cycles of neoadjuvant systemic therapy.
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
Annelot G.J. van Rosssum,Marleen Kok,Danielle McCool,Mark Opdam,Nienke C. Miltenburg,I.A.M. Mandjes,A. Elise van Leeuwen-Stok,Alex L. T. Imholz,Johanneke E.A. Portielje,Monique M.E.M. Bos,Aart van Bochove,Erik van Werkhoven,Marjanka K. Schmidt,HM Oosterkamp,Sabine C. Linn +14 more
TL;DR: In this independent replication, an association between 2 out of 13 SNPs and chemotherapy toxicities could be replicated, warranting further validation in order to enable tailored treatment for breast cancer patients.
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.
Leonora W. de Boo,K. Jóźwiak,Natalie D. ter Hoeve,P. J. Van Diest,Mark Opdam,Y. Wang,M. K. Schmidt,V. D. de Jong,Sieta Kleiterp,S. Cornelissen,D. Baars,R. H. T. Koornstra,E. D. Kerver,Thijs van Dalen,A. D. Bins,A. Beeker,S. M. van den Heiligenberg,P. C. de Jong,S. D. Bakker,R. C. Rietbroek,I.R. Konings,R. Blankenburgh,R. M. Bijlsma,Alex L. T. Imholz,N. Stathonikos,Willem Vreuls,J. Sanders,E. H. Rosenberg,Esther A. Koop,Z. Varga,C. V. van Deurzen,A. L. Mooyaart,A. Córdoba,E. Groen,J. Bart,S. M. Willems,Vicky Zolota,J. Wesseling,A. Sapino,Ewa Chmielik,A. Ryška,A. Broeks,Ac. Voogd,E. Van Der Wall,S. Siesling,R. Salgado,Gwen M. H. E. Dackus,M. Hauptmann,Marleen Kok,S. C. Linn +49 more
TL;DR: This study evaluates the prognostic value of histopathologic traits in young, chemotherapy-naïve patients with early-stage triple-negative breast cancer, finding lymphovascular invasion, fibrotic focus, and stromal tumor-infiltrating lymphocytes as independent predictors of breast cancer-specific survival.
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
R. T. Lugtenberg,Stefanie de Groot,Ad A. Kaptein,Maarten J. Fischer,Elma Meershoek-Klein Kranenbarg,Marjolijn Duijm-de Carpentier,Danielle Cohen,Hiltje de Graaf,Joan B. Heijns,Johanneke E.A. Portielje,Agnes J. van de Wouw,Alex L. T. Imholz,LW Kessels,Suzan Vrijaldenhoven,Arnold Baars,Marta Fiocco,Jacobus J M van der Hoeven,Hans Gelderblom,Valter D. Longo,Hanno Pijl,Judith R. Kroep +20 more
TL;DR: FMD as an adjunct to neoadjuvant chemotherapy appears to improve certain QoL and illness perception domains in patients with HER2-negative breast cancer.